← Leaderboards
Mark A Gregory
University Of Colorado Denver
$746,253
Attributed
$746,253
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $136K · FY2009–14$200K$150K$100K$50K$0
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$746,253 · 2
By mechanism
K22$407,904 · 1
K01$338,349 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Francesca Alvarez Calderon$142,364
- Hae J Park$153,008
- Elizabeth J Shpall$12,617,686
- Mario Luis Santiago$9,294,870
- Natalie J Serkova$3,493,253
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceChronic Myeloid LeukemiaInhibitor/AntagonistProteinsSignal PathwayTyrosine Kinase InhibitorGenesImatinibKillingsPathway InteractionsResponseRna InterferenceSmall Hairpin RnaSmall MoleculeCombined Modality TherapyCell KillingCellsGenome-WideIn VitroIn VivoLeukemiaMouse ModelCalmodulin-Dependent Protein Kinase IiCalcium Signaling
Grant awards (6)
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy$135,968
K22 · FY2014 · CA · contact PI
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy$135,968
K22 · FY2013 · CA · contact PI
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy$135,968
K22 · FY2012 · CA · contact PI
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML$115,170
K01 · FY2011 · CA · contact PI
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML$112,760
K01 · FY2010 · CA · contact PI
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML$110,419
K01 · FY2009 · CA · contact PI